Remove 2018 Remove Hospitals Remove Immune Response
article thumbnail

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine

The Pharma Data

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

article thumbnail

Laurie Glimcher

Broad Institute

She is also a member of the board of trustees of the Massachusetts Health & Hospital Association. A trailblazer in cancer research, Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

2018 for patients with severe asthma, without an eosinophilic phenotype. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. 6-8 Patients with severe asthma account for twice as many asthma-related hospitalizations. 2018; 9: 1595.

Trials 52
article thumbnail

Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease

The Pharma Data

Additionally, oral capsules provide the convenience of home use, and increase patient compliance by eliminating the need for infusions in a clinic or hospital setting. Grand View Research August 2018 ( [link] ). Cited References: 1. Tiziana Life Sciences January 9, 2020 Press Release ( [link] ). da Cunha, A. and Weiner, H.

article thumbnail

New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients.

The Pharma Data

. “This new analysis from NAVIGATOR is exciting for the up to one in five severe asthma patients who have comorbid nasal polyps,” said Professor Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, UK, the principal investigator of the NAVIGATOR trial.

Trials 52
article thumbnail

Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women

The Pharma Data

1 This decision follows the FDA’s November 2018 decision to grant Fast Track status to RSVpreF. million outpatient visits and 58,000 hospitalizations occur each year among children younger than five years old. RSV infections account for approximately 177,000 hospitalizations and 14,000 deaths each year.

Virus 52
article thumbnail

Tezepelumab granted Priority Review by U.S. FDA

The Pharma Data

Tezepelumab was granted an FDA Breakthrough Therapy Designation for patients with severe asthma without an eosinophilic phenotype in September 2018. 2,6,9) Patients with severe uncontrolled asthma have twice the risk of asthma-related hospitalizations.(10,11) 2018; 10 (1): 34-45. 2018; 3: 60-9. About Severe Asthma.

FDA 52